Dr. Andrew Huberman Joins Hims & Hers Board of Directors
Dr. Andrew Huberman Joins Hims & Hers Board of Directors
World-renowned neuroscientist and tenured Stanford professor brings valuable expertise to the company on making the latest health innovations accessible and actionable
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109410346/en/

Dr. Huberman is a world-renowned neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He has authored or co-authored more than 75 peer-reviewed articles in respected scientific journals including Nature, Science, Cell, Neuron, Current Biology, and Journal of Neuroscience. Research from his laboratory at Stanford, the Huberman Laboratory, has advanced our understanding of brain development, neural plasticity, and the neural mechanisms of stress and resilience.
Dr. Huberman has become a trusted cultural voice on the latest health and wellness science for people all over the world. As the host of the podcast Huberman Lab, the most popular health and science podcast in the world, he translates science into real-life protocols for millions of people, and his book Protocols: An Operating Manual for the Human Body is a #1 New York Times bestseller.
“Andrew Huberman has done more than almost anyone to make rigorous science accessible and actionable for millions of people,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “As we continue to build the future of personalized, science-backed healthcare, his expertise in neuroscience and human health will sharpen how we think about the science behind our offerings. We’re thrilled to welcome him to our board of directors.”
“Tools to significantly improve human health are emerging faster than ever,” said Andrew Huberman. “Everyone deserves access to the best possible healthcare and tools to feel great. Hims & Hers provides the ideal platform to deliver personalized health. I’m delighted to join the board of Hims & Hers because they are clearly the leaders in this effort, and are transforming an industry of personalized healthcare that, in the past, has been too slow to prioritize everyday people. I’m incredibly proud to be part of the mission to set a new standard for delivering personalized healthcare that allows everyone to feel their absolute best in terms of health, vigor, and longevity.”
Dr. Huberman joins a multi-disciplinary board that includes experts in clinical practice, pharmaceuticals, regulatory affairs, retail, technology, and foreign policy. He will also serve as a scientific and brand marketing advisor to Hims & Hers and separately provide additional marketing support to the company through the Huberman Lab podcast.
About Hims & Hers Health, Inc.
Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.himsandhershealth.com.
Press Contact
Abby Reisinger-Moley
press@forhims.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261109410346/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

4 Growth Stocks to Buy While They’re Still Undervalued

3 of the Best Core Stocks to Own

3 Great New ETFs From 2026

Retirees: 5 Reasons to Consider Index Funds and ETFs
